Keywords: boehringer, ingleheim, viramune, achieves, durable, patient, benefit

Boehringer Ingleheim's Viramune achieves durable patient benefit in HIV trial

Article | 05 February 2007

Long-term data from the NEFA (Nevirapine/Efavirenz/Abacavir) study indicates, according to German pharmaceutical firm Boehringer Ingleheim, that HIV-infected patients ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Drugs

Nevirapine

Viramune

Efavirenz

Sustiva

Go to drug listing